IDYA vs WERN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IDYA and WERN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IDYA and WERN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) is a clinical-stage precision-medicine oncology company that designs targeted therapies for molecularly defined solid tumors. Its scientific engine is synthetic lethality, an approach that exploits genetic vulnerabilities specific to cancer cells, supported by an in-house DECIPHER CRISPR platform for target and biomarker discovery. The lead asset, darovasertib (IDE196), is a protein kinase C inhibitor being developed for uveal melanoma, a rare and hard-to-treat eye cancer, in both the metastatic setting (with crizotinib, partnered with Servier) and as neoadjuvant and adjuvant therapy for primary disease. Behind it sits a pipeline including IDE397 (MAT2A inhibitor) for MTAP-deleted cancers, IDE849 (a DLL3-targeting topoisomerase-I ADC), IDE161 (PARG), IDE275 (Werner helicase), and IDE705 (Pol-theta helicase).

Full IDYA guide

Werner Enterprises, Inc. is a transportation and logistics company that moves freight across North America. Its business splits into two main segments: Truckload Transportation Services (TTS), which includes the contract-based Dedicated fleet and the more spot-exposed One-Way Truckload operation, and Werner Logistics, an asset-light brokerage, intermodal, and supply-chain unit. The company has been deliberately tilting its portfolio toward Dedicated, which is contract-driven, more resilient through downturns, and protected by higher barriers to entry, and the early-2026 acquisition of dedicated carrier FirstFleet for roughly $245 million made Werner one of the five largest dedicated carriers in the country.

Full WERN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• IDYA drivers: Darovasertib approval and launch in uveal melanoma; Synthetic-lethality and precision pipeline breadth.
• WERN drivers: Shift toward Dedicated trucking; FirstFleet acquisition and scale.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a clinical-stage biotech, IDEAYA has minimal product revenue and posts ongoing operating losses, so the equity is valued on pipeline expectations that can swing sharply on trial and regulatory news. For WERN, werner's core truckload business is deeply cyclical, so a prolonged freight recession keeps rates and volumes depressed and can push the company back into losses, as the soft 2025 showed.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IDYA if you believe its drivers more; WERN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IDYA and WERN guides.

IDYA. IDEAYA is pre-product-revenue, so traditional multiples like P/E do not apply and the market values it on pipeline probability and cash runway rather than earnings. The roughly $973 million cash balance against a market cap in the low-single-digit billions means a large share of the valuation sits in the balance sheet plus darovasertib option value. Consensus analyst sentiment has been broadly positive, though price targets were trimmed during 2026 (for example RBC to $48), reflecting how tightly the shares track clinical and regulatory expectations.

WERN. Werner reported about $3.0 billion in revenue in 2025, down slightly year over year, and swung to losses in the weakest quarters of a soft freight market. First-quarter 2026 revenue rose 14 percent to about $809 million and adjusted earnings turned modestly positive, helped by the FirstFleet acquisition and firmer rates. At around $43 per share the market cap sits near $2.6 billion, and the trailing P/E is negative because of the recent net loss, so valuation hinges on a freight recovery and improving Dedicated margins rather than current profits.

Headline figures (approximate, July 2026): IDYA shows product revenue ~$0 (pre-commercial; Q1 2026 collaboration revenue ~$6.6M), cash & marketable securities ~$973M (Mar 31, 2026), cash runway guided into 2030, market cap ~$2.5-3.2B; WERN shows revenue (2025) ~$3.0B, q1 2026 revenue ~$809M (+14% YoY), market cap ~$2.6B, p/e ratio (ttm) ~negative (net loss).

IDYA and WERN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IDYA and WERN exposure against your real portfolio. It is not an investment adviser.